Objective Health Challenge:PreEclampsia (PE) claims the lives of 75,000 women annually and the 6,000,000+ surviving mothers will have an increased risk of cardiovascular disease for the rest of their life. PE accounts for over 500,000 infant deaths worldwide every year1; and for the millions of babies that survive, they too will go on to have increased risk of a variety of health issues. PE is a syndrome that develops during pregnancy but presents no clinical symptoms during most of the pregnancy and is therefore currently complex to diagnose. Business Challenge:With an annual spend of over 31Billion in direct costs in the developed world alone, the provision of antenatal care to pregnant women has a significant impact on health care budgets; dealing with the immediate consequences of PE form an important contribution to this cost. The Preelampsia foundation (http://www.preeclampsia.org/) estimates the annual cost of PE is more than $7billion in the US. InformBio Business Innovation:InformBio (IB) has licensed pioneering research by Dr.Vesna Garovic of the Mayo Clinic, USA. The technology has identified podocyte specific biomarkers in urine that indicate ongoing renal damage and which allow for a sub-clinical diagnosis for PE. The key biomarker, podocin, has demonstrated exceptional sensitivity and specificity and can diagnose the disease up to 3 months before clinical symptoms emerge3. InformBio are currently working to develop flow cytometry and research use only (RUO) ELISA assays for the biomarker. InformBio’s ambition is to be the world leader in early pregnancy prognostic tests, offering the most innovative, cost effective solutions to predict pregnancy complications. Phase 1 proposal:To conduct a feasibility study to support the development of a detailed business plan for the introduction of a PE diagnostic test. Fields of science medical and health sciencesclinical medicineobstetricsfetal medicinemedical and health sciencesclinical medicinecardiologycardiovascular diseasessocial scienceseconomics and businesseconomicssustainable economysocial scienceseconomics and businesseconomicshealth economics Programme(s) H2020-EU.3.1. - SOCIETAL CHALLENGES - Health, demographic change and well-being Main Programme H2020-EU.3.1.3. - Treating and managing disease Topic(s) PHC-12-2014-1 - Clinical research for the validation of biomarkers and/or diagnostic medical devices Call for proposal H2020-SMEInst-2014-2015 See other projects for this call Sub call H2020-SMEINST-1-2014 Funding Scheme SME-1 - SME instrument phase 1 Coordinator INFORM BIOSCIENCE LIMITED Net EU contribution € 50 000,00 Address Hoffman park little island county cork Cork Ireland See on map SME The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed. Yes Region Ireland Southern South-East Activity type Private for-profit entities (excluding Higher or Secondary Education Establishments) Links Contact the organisation Opens in new window Participation in EU R&I programmes Opens in new window HORIZON collaboration network Opens in new window Other funding € 21 429,00
